Company intelligence / Profile preview

Allergy Therapeutics PLC

Worthing, West Sussex, United Kingdomallergytherapeutics.co.uk ↗

Ownership: Private
Development stage: Commercial

Overview

Currently conducting Phase I/IIa PROTECT trial for VLP Peanut vaccine with Part A completed in April 2023 showing no safety signals in healthy volunteers. Part B is ongoing at 10 US clinical sites with 36 peanut-allergic patients receiving three escalating doses. The company also has a Phase 3 ragweed pollen hypersensitivity treatment in development.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: VaccinesSubcutaneous immunotherapyVirus-like particle (VLP) technologyAdjuvant systems
Industry: Biotech

Drug pipeline

30 assets

Pollinex Quattro Ragweed

29 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Allergy Therapeutics PLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allergy Therapeutics PLC.

Explore the full profile